CSCO BC guideline: updates for hormone receptor-positive breast cancer in 2020-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CSCO BC guideline: updates for hormone receptor-positive breast cancer in 2020

Published:2020-04 Issue: Volume:1 Page:3-3
ISSN:2218-6778
Container-title:Translational Breast Cancer Research
language:
Short-container-title:Transl Breast Cancer Res

Author:

Xu Fengrui,Jiang Zefei

Publisher

AME Publishing Company

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer;Chinese Medical Journal;2023-04-27

2. Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer;Annals of Translational Medicine;2021-10

3. Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study;Annals of Translational Medicine;2021-05

4. Potential biomarkers of resistance to CDK4/6 inhibitors: a narrative review of preclinical and clinical studies;Translational Breast Cancer Research;2021-04

5. Occurrence and distribution of bone metastases in 984 metastatic breast cancer patients;Translational Breast Cancer Research;2021-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3